证券代码：688576 证券简称：西山科技 公告编号：2025-040 重庆西山科技股份有限公司 关于公司董事辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 重庆西山科技股份有限公司（以下简称"公司"）董事会于近日收到公司董 事张威亚女士的《关于辞去董事职务的辞职报告》，张威亚女士因工作调动原因 申请辞去公司董事职务。根据《公司法》《公司章程》及有关法律法规的规定， 张威亚女士的辞任申请自辞职报告送达公司董事会时生效，张威亚女士辞任未导 致公司董事会成员人数低于法定人数，不会影响公司董事会的正常运行，其职务 变动不会对公司正常经营活动产生不利影响。 | 是否存在 | 是否继续在上 | 原定任期 | 具体职务 | 未履行完 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 辞任职务 | 辞任时间 | 离任原因 | 市公司及其控 | 到期日 | ...

Core Viewpoint - Xishan Technology (688576.SH) faces potential joint compensation claims exceeding 35.71 million yuan due to alleged price inflation of medical devices recognized by the 301 Hospital of the People's Liberation Army [1][2] Group 1: Arbitration Claims - The arbitration claims from China National Pharmaceutical Group United Medical Devices Co., Ltd. and China National Pharmaceutical Group Beijing United Meidi Medical Devices Co., Ltd. total approximately 35.71 million yuan, with specific compensation obligations and amounts yet to be determined [1][2] - The claims include a demand for the return of over 20.3 million yuan due to price inflation for medical consumables delivered to the 301 Hospital from June 2019 to October 2021 [2] Group 2: Company Financials - In the first half of 2025, Xishan Technology reported revenue of 155 million yuan and a net profit of 34.38 million yuan, indicating that the arbitration amount exceeds the company's net profit for that period [3] - The company specializes in minimally invasive surgical medical devices and has established itself as a leading player in the surgical power device sector in China, with products sold to nearly a thousand tertiary hospitals [3] Group 3: IPO Implications - The timing of the arbitration claims is notable as they were made in 2023, coinciding with Xishan Technology's IPO application, which could impact the company's ability to go public and its financial metrics [4] - The company's prospectus details that pricing for products is determined by distributors and hospitals through bidding processes, indicating that Xishan Technology does not participate in end pricing [4][5] Group 4: Distributor Relationships - The distributor involved, Dejuhe Medical Technology Co., Ltd., was not among Xishan Technology's top five distributors from 2020 to 2022, raising questions about the claims of joint liability for price inflation [5]

Group 1 - The core viewpoint of the news highlights the positive performance of the AI-focused ETF, with a 0.75% increase and significant trading activity, indicating a strong market interest in AI-related stocks [1][2] - Key stocks within the ETF include Stone Technology, which rose by 5.93%, Lingyun Optics with a 4.58% increase, and Sikan Technology up by 3.69%, showcasing the strong performance of leading companies in the AI sector [1] - The overall trading volume exceeded 21 million yuan, reflecting active market participation and robust liquidity [1] Group 2 - Huawei's announcement on September 16 outlines ten major technological trends for an intelligent world by 2035, predicting a 100,000-fold increase in total computing power and significant innovations in computing architecture and paradigms [1] - According to招商证券, both domestic and international demand for computing power remains high, with global AI infrastructure spending continuing at elevated levels, as evidenced by Nvidia's FY26Q2 performance meeting expectations [1] - Domestic computing companies are expected to continue delivering strong results, with recent developments such as Cambrian's capital increase approval and Haiguang's acquisition progress indicating confidence in future performance [1]

Core Viewpoint - Chongqing Xishan Technology Co., Ltd. is involved in arbitration matters, with the arbitration tribunal having accepted the case but not yet convened. The company is one of the respondents and may bear joint liability for compensation [1] Group 1: Arbitration Details - The company has received materials related to two arbitration cases from the Beijing Arbitration Commission, with the claimants being China National Pharmaceutical Group United Medical Devices Co., Ltd. (referred to as "Guoyao United") and China National Pharmaceutical Group Beijing United Meidi Medical Devices Co., Ltd. (referred to as "Guoyao Beijing United Meidi") [2] - In the first arbitration case, Guoyao United claims that it is not at fault for the pricing issues related to medical supplies delivered to 301 Hospital, which were found to exceed the national minimum price, and seeks joint compensation of 20.300398 million yuan and legal fees of 630,000 yuan from the respondents [2] - In the second arbitration case, Guoyao Beijing United Meidi similarly claims it is not responsible for the pricing issues and seeks joint compensation of 14.2746 million yuan and legal fees of 509,400 yuan from the respondents [2] Group 2: Company Response - The company's board has begun organizing defense materials and has hired a professional legal team to actively respond to the arbitration [3] - The company asserts that the pricing of the medical supplies in question was in line with commercial practices and found no evidence of inflated prices [3] - Initial legal consultations suggest that the arbitration cases are not expected to have a significant impact on the company's daily operations [3]

证券代码：688576 证券简称：西山科技 公告编号：2025-039 重庆西山科技股份有限公司 关于参加重庆辖区上市公司 2025 年投资者网上集体 接待日暨半年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 9 月 17 日 为进一步提高辖区上市公司投资者关系管理水平，促进公司完善公司治理， 助力上市公司高质量发展，在重庆证监局指导下，重庆上市公司协会联合深圳市 全景网络有限公司举办"重庆辖区上市公司 2025 年投资者网上集体接待日暨半 年度业绩说明会活动"。 本次活动将于 2025 年 9 月 25 日（星期四）15:00-17:00 举行，投资者可以 登录"全景路演"平台（https://rs.p5w.net）参与本次活动。届时公司相关高 级管理人员将参加本次活动，通过网络在线交流形式，就投资者关心的问题，与 投资者进行"一对多"形式的在线沟通与交流，欢迎广大投资者踊跃参与。 重庆西山科技股份有限公司董事会 特此公告。 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-038 重庆西山科技股份有限公司 关于公司涉及仲裁事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 二、仲裁案件的基本情况 （一）国药联合仲裁申请事项 1、仲裁当事人 申请人：国药集团联合医疗器械有限公司 被申请人一：北京德聚和医疗技术有限公司 案件所处的仲裁阶段：仲裁庭已受理，尚未开庭。 上市公司所处的当事人地位：重庆西山科技股份有限公司（以下简称"公 司"）为被申请人之一，承担连带赔偿责任。 涉案金额：根据对方提交的仲裁申请书等文件，具体赔偿义务及金额尚 不明确（两起仲裁案件初步提出了合计约 3,571 万元的主张，详见公告正文）。 对上市公司影响：经对案件情况进行梳理，公司与代理商北京德聚和医 疗技术有限公司（以下简称"德聚和"，与公司无关联关系）之间针对本案所涉 耗材产品的交易定价符合商业惯例，未发现价格虚高情况；同时，经初步咨询律 师意见，认为该仲裁案件不会对公司日常生产经营产生重大影响。公司将聘请专 业律师团队积极应诉，切 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-037 重庆西山科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 说明会类型 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 8 月 30 日在上 海证券交易所网站（www.sse.com.cn）披露《2025 年半年度报告》。为便于广大 投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司计划于 2025 年 9 月 19 日（星期五）15:00-16:00 在"价值在线"（www.ir-online.cn）举 办重庆西山科技股份有限公司 2025 年半年度业绩说明会，与投资者进行沟通和 交流，广泛听取投资者的意见和建议。 （如遇特殊情况，参会人员可能进行调整） 四、 投资者参加方式 投 资 者 可 于 2025 年 9 月 19 日 （ 星 期 五 ） 15:00-16:00 通 过 网 址 https://eseb.cn/1rsjDTKgLPG 或使用 ...

Summary of Key Points Core Viewpoint - Xishan Technology reported a decrease in the number of shareholders and a decline in stock performance, alongside mixed financial results for the first half of the year [2]. Shareholder and Stock Performance - As of August 31, the number of shareholders for Xishan Technology was 5,078, a decrease of 360 from the previous period (August 20), representing a decline of 6.62% [2]. - The closing price of Xishan Technology was 68.85 yuan, reflecting an increase of 1.58%, but the stock has cumulatively decreased by 3.64% since the concentration of shares began [2]. - The stock experienced 2 days of increase and 6 days of decrease during the reporting period [2]. Financing and Margin Data - As of August 29, the latest margin trading balance for the stock was 77.9726 million yuan, with the entire financing balance decreasing by 2.62%, amounting to a reduction of 2.0957 million yuan [2]. Financial Performance - For the first half of the year, Xishan Technology achieved operating revenue of 155 million yuan, representing a year-on-year growth of 2.40% [2]. - The net profit for the same period was 34.382 million yuan, showing a significant decline of 41.62% year-on-year [2]. - The basic earnings per share were reported at 0.7600 yuan, with a weighted average return on equity of 1.97% [2].

Group 1 - The company reported a revenue of 155 million yuan for the first half of 2025, representing a year-on-year growth of 2.40% [1] - The net profit attributable to the parent company was 34.38 million yuan, with basic earnings per share of 0.76 yuan [1] - The net cash flow from operating activities improved significantly to 17.53 million yuan compared to the same period last year [1] Group 2 - The company emphasized its commitment to independent research and development, with R&D investment reaching 24.74 million yuan, a year-on-year increase of 7.52%, accounting for 15.96% of revenue [2] - The company completed 85 patent applications and received 74 authorized patents, including 21 invention patents [2] - The company has made progress in the field of flexible endoscopes by forming a specialized technical team to overcome core technological bottlenecks [2] Group 3 - The company aims to maintain its strategic positioning as a provider of overall solutions for minimally invasive surgical tools, focusing on product iteration and brand promotion [3] - The company plans to enhance the flexibility of its R&D and marketing systems while improving operational processes and internal controls [3] - The company is committed to strengthening its core competitive advantages through effective supply chain management and product quality [3]

Core Insights - Xishan Technology achieved a total operating revenue of 155 million yuan in the first half of 2025, representing a year-on-year growth of 2.4%, and a net profit attributable to shareholders of 34.38 million yuan [1] - The company continues to adhere to its strategic positioning as a provider of overall solutions for minimally invasive surgical tools, expanding its business lines while responding to changes in the economic environment and regulatory trends in the medical device industry [1] Group 1: R&D and Innovation - The company emphasizes independent R&D innovation, with R&D investment amounting to 24.74 million yuan, a year-on-year increase of 7.52%, accounting for 15.96% of total operating revenue [1][2] - A total of 85 patent applications were completed, with 74 patents granted during the reporting period, and the company added 2 Class III medical device registration certificates and 8 Class II medical device registration certificates [2] - The company is focusing on strategic projects for innovation breakthroughs and enhancing its competitive advantage in surgical power devices through strategic allocation of R&D resources and equipment iteration [2] Group 2: Production Capacity and Manufacturing - The company has significantly increased its production facility area with the full utilization of a new park, laying a hardware foundation for future capacity enhancement [2] - It is strengthening its core component production capabilities through automation and modular production, implementing a comprehensive traceability and data loop system from raw material intake to finished product delivery [2] Group 3: Market Expansion and Sales - The company is enhancing its end-sales channel construction by focusing on hospital user development, increasing user numbers, and boosting existing users' equipment and consumable usage to rapidly improve market share [3] - Xishan Technology has established a rich product matrix covering various departments such as neurosurgery, ENT, orthopedics, breast surgery, general surgery, and gynecology, providing comprehensive solutions for multiple scenarios [3] - The company is increasing its investment in international registration and promotion, expanding its overseas market presence, with products now covering 46 countries and regions as of the first half of 2025 [3]